NanoBio Corporation Secures Novel Antigen Source Through National Institutes of Health (NIH) for its Intranasal RSV Vaccine

ANN ARBOR, Mich.--(BUSINESS WIRE)--NanoBio® Corporation today announced a licensing agreement with the National Institutes of Health (NIH) that represents a significant step forward in developing the first vaccine to protect against respiratory syncytial virus (RSV) infections. The agreement provides NanoBio with rights to a novel RSV antigen, developed by the NIH using proprietary viral-selection and reverse-genetics technology.

Back to news